NovaBridge Biosciences
NBP$427M
Small CapNASDAQBiotechnology🇺🇸North America32 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jan 1, 2027
42wMarket Overview
Stock performance and key metrics
NBP News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Liquid 13-Cis Retinoic Acid
Neuroblastoma
Oral Hydroxyurea (100 mg/mL) Solution
Sickle Cell Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liquid 13-Cis Retinoic Acid | Phase 2 | Neuroblastoma | - | - |
Oral Hydroxyurea (100 mg/mL) Solution | Phase 2 | Sickle Cell Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply